Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CYBN SEC filings page on Stock Titan aggregates Cybin Inc.’s regulatory disclosures as a foreign issuer, giving investors structured access to the company’s official documents. Cybin files with the U.S. Securities and Exchange Commission primarily on Form 40-F and Form 6-K, and also uses Form 25 for listing changes. These filings are central to understanding the company’s clinical-stage neuropsychiatry business, its capital structure, and its transition between stock exchanges.
Form 6-K submissions for Cybin typically include interim consolidated financial statements, management’s discussion and analysis, certifications of interim filings, and news releases. Many 6-Ks also incorporate material change reports, equity distribution agreements, and prospectus-related documents by reference into Cybin’s registration statements on Form F-10. For a company developing drug candidates such as CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, these filings provide context on how clinical programs are funded and governed.
The filings page also features Cybin’s Form 25, which notifies the SEC of the voluntary removal of its common shares from listing and registration on the NYSE American. This document confirms that the company has complied with the exchange’s rules and the requirements for voluntary withdrawal, and it aligns with Cybin’s news release describing its plan to transfer its U.S. listing to the Nasdaq Global Market and to change its trading symbol from CYBN to HELP.
On Stock Titan, each new Cybin filing from EDGAR is captured and presented with AI-powered summaries that explain the purpose and key points of documents such as 6-Ks, F-10 registration statements, and the Form 25 delisting notice. This helps readers quickly understand how Cybin reports its financial results, documents material changes, and manages its listing status, while still allowing direct access to the underlying SEC filings for detailed review.
Cybin Inc. submitted a Form 6-K as a foreign private issuer for November 2025. The filing mainly serves a technical purpose by stating that Exhibit 99.1 from this report is incorporated by reference into Cybin’s existing Form F-10 registration statement, allowing that exhibit to be treated as part of the registration materials.
Cybin Inc. (CYBN): Schedule 13G/A Amendment No. 2 filed by Point72 entities reporting beneficial ownership of Cybin common shares. The filing lists 6,410,778 Common Shares beneficially owned with shared voting and dispositive power and 0 under sole power, representing 9.9% of the class as of the close of business on November 13, 2025.
The reported amount includes 2,109,338 Common Shares issuable upon exercise of warrants, which are subject to a 9.99% beneficial ownership blocker; some warrants are not presently exercisable due to this cap. As context, the aggregate percentage as of September 30, 2025 was based on 25,188,217 Common Shares outstanding as of September 16, 2025. The filing also notes that as of September 30, 2025, the reporting person may have been deemed to beneficially own 1,239,629 Common Shares, or 4.9%.
Ownership is held through Point72 Associates, LLC under an investment management agreement; Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen are reporting persons. They certify the securities were not acquired to change or influence control.
Cybin Inc. furnished a Form 6-K for November 2025, making available interim consolidated financial statements and the related MD&A for the three and six months ended September 30, 2025. The filing also includes CEO and CFO certifications and a news release dated November 13, 2025.
Exhibits 99.1 and 99.2 are incorporated by reference into Cybin’s Registration Statement on Form F-10 (File No. 333-289139). Cybin reports annually on Form 40-F.
Cybin Inc. (CYBN): Venrock-affiliated entities and individuals filed a Schedule 13G reporting beneficial ownership of 5,111,412 common shares, representing 9.99% of the class as of the 10/31/2025 event date.
The stake comprises common shares plus pre-funded warrants and common warrants, all subject to a 9.99% Beneficial Ownership Blocker. The percentage is based on 27,616,381 common shares outstanding as of 10/28/2025, 22,277,750 shares issued in a registered direct offering that closed on 10/31/2025, and 1,271,162 shares issuable upon warrant exercise. Cover-page percentages are rounded down to 9.9% due to EDGAR limits.
The reporting group includes Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, L.L.C., Venrock Healthcare Capital Partners EG, L.P., their managers, and individuals Nimish Shah and Bong Y. Koh. They certified the holdings were not acquired to change or influence control.
Cybin Inc. (CYBN) received a Schedule 13G showing that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively report beneficial ownership of 3,072,250 common shares, representing 6.09% of the class as of the reported date.
The filing lists shared voting and dispositive power over 3,072,250 shares and no sole voting or dispositive power. The ownership calculation references 50,431,381 shares, derived from 49,894,131 shares outstanding as of October 28, 2025 plus 537,250 warrants that are exercisable subject to a 9.99% Maximum Percentage beneficial ownership cap. The certification states the securities were not acquired to change or influence control.